Sensitivity to Neutralizing Antibodies and Resistance to Type I Interferons in SARS-CoV-2 R.1 Lineage Variants, Canada
Emerging Infectious Diseases · 2023
DOI: 10.3201/eid2907.230198 ↗Kurz gefasst
Fachartikel in der Zeitschrift Emerging Infectious Diseases, 2023. Verfasst von Rajesh Abraham Jacob und 24 weiteren Autor:innen. Hauptthemen laut MEDLINE: Interferon Type I, COVID-19. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CIHR.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Förderung
- CIHR
Zitieren
APA
Jacob, R. A., Zhang, A., Ajoge, H. O., D'Agostino, M. R., Nirmalarajah, K., Shigayeva, A., Demian, W. L., Baker, S. J. C., Derakhshani, H., Rossi, L., Nasir, J. A., Panousis, E. M., Draia, A. N., Vermeiren, C., Gilchrist, J., Smieja, N., Bulir, D., Smieja, M., Surette, M. G., …, & Mossman, K. (2023). Sensitivity to Neutralizing Antibodies and Resistance to Type I Interferons in SARS-CoV-2 R.1 Lineage Variants, Canada. Emerging Infectious Diseases. https://doi.org/10.3201/eid2907.230198
Vancouver
Jacob RA, Zhang A, Ajoge HO, D'Agostino MR, Nirmalarajah K, Shigayeva A, et al. Sensitivity to Neutralizing Antibodies and Resistance to Type I Interferons in SARS-CoV-2 R.1 Lineage Variants, Canada. Emerging Infectious Diseases. 2023. doi:10.3201/eid2907.230198
BibTeX
@article{Jacob2023,
author = {Jacob, Rajesh Abraham and Zhang, Ali and Ajoge, Hannah O and D'Agostino, Michael R and Nirmalarajah, Kuganya and Shigayeva, Altynay and Demian, Wael L and Baker, Sheridan J C and Derakhshani, Hooman and Rossi, Laura and Nasir, Jalees A and Panousis, Emily M and Draia, Ahmed N and Vermeiren, Christie and Gilchrist, Jodi and Smieja, Nicole and Bulir, David and Smieja, Marek and Surette, Michael G and McArthur, Andrew G and McGeer, Allison J and Mubareka, Samira and Banerjee, Arinjay and Miller, Matthew S and Mossman, Karen},
title = {Sensitivity to Neutralizing Antibodies and Resistance to Type I Interferons in SARS-CoV-2 R.1 Lineage Variants, Canada},
journal = {Emerging Infectious Diseases},
year = {2023},
doi = {10.3201/eid2907.230198}
}
EUVIMED